1.74 USD
↘ 1.40 (44.60%)AT CLOSE (11:59 AM EDT)
BioAtla, Inc. Common Stock
BCABNASDAQ • USD
1.74
↗ 0.01 (0.29%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
1.74
↗ 0.01 (0.29%)
Market: CLOSED
BioAtla, Inc. Common Stock (BCAB) trades at $1.79 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (86.8%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, BCAB appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Aug 28, 2026.
Open?$1.58
High?$2.10
Low?$1.51
Prev. Close?$3.14
Volume?1.0M
Avg. Volume?62.4K
VWAP?$1.76
Rel. Volume?16.56x
Bid / Ask
Bid?$1.48 × 100
Ask?$2.05 × 100
Spread?$0.57
Midpoint?$1.77
Valuation & Ratios
Market Cap?5.2M
Shares Out?N/A
Float?1.4M
Float %?84.7%
P/E Ratio?N/A
P/B Ratio?-0.14
EPS?-$18.88
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
Employees
41
Market Cap
5.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2020-12-16
Address
11085 TORREYANA ROAD
SAN DIEGO, CA 92121
Phone: 858-558-0708
SAN DIEGO, CA 92121
Phone: 858-558-0708
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?36
Piotroski F-Score?0/9Weak
Altman Z-Score?-93.53Distress
Confidence?49%Low
Short InterestElevated
Short % of Float?9.88%Elevated
Short Interest?138.9K
Days to Cover?2.0
Free Float1.4M
Avg Daily Volume69.4K
Settlement Date2026-08-14
Financial Health
Current Ratio?0.20Weak
Quick Ratio?0.20Weak
Cash Ratio?0.07Low
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-0.14CHEAP▾
S&P97
P/S?0.62CHEAP▾
Peers100
S&P93
P/FCF?N/A▾
EV/EBITDA?-0.1CHEAP▾
S&P97
EV/Sales?0.43CHEAP▾
Peers100
S&P97
Returns & Efficiency
ROE?86.8%STRONG▾
Peers50
S&P97
ROA?-330.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-23482000
Enterprise Value?$3.7M
Fundamentals ratios updated end of day